Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course
Informazioni aggiuntive
Autori
Muri J.,
Cecchinato V.,
Cavalli A.,
Shanbhag A. A.,
Matković M.,
Biggiogero M.,
Maida P. A.,
Moritz J.,
Toscano C.,
Ghovehoud E.,
Furlan R.,
Barbic F.,
Voza A.,
De Nadai G.,
Cervia C.,
Zurbuchen Y.,
Taeschler P.,
Murray L. A.,
Danelon-Sargenti G.,
Moro S.,
Gong T.,
Piffaretti P.,
Bianchini F.,
Crivelli V.,
Podešvová L.,
Pedotti M.,
Jarrossay D.,
Sgrignani J.,
Thelen S.,
Uhr M.,
Bernasconi E.,
Rauch A.,
Manzo A.,
Ciurea A.,
Rocchi M. B. L.,
Varani L.,
Moser B.,
Bottazzi B.,
Thelen M.,
Fallon B. A.,
Boyman O.,
Mantovani A.,
Garzoni C.,
Franzetti-Pellanda A.,
Uguccioni M.,
Robbiani D.
Tipo
Articolo pubblicato in rivista scientifica
Anno
2023
Lingua
Inglese
Sommario
Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are associated with adverse coronavirus disease 2019 (COVID-19) outcomes. Here we discovered that antibodies against specific chemokines were omnipresent post-COVID-19, were associated with favorable disease outcome and negatively correlated with the development of long COVID at 1 yr post-infection. Chemokine antibodies were also present in HIV-1 infection and autoimmune disorders, but they targeted different chemokines compared with COVID-19. Monoclonal antibodies derived from COVID-19 convalescents that bound to the chemokine N-loop impaired cell migration. Given the role of chemokines in orchestrating immune cell trafficking, naturally arising chemokine antibodies may modulate the inflammatory response and thus bear therapeutic potential.
Periodico
Nature immunology
Volume
24
Pagine (o numero dell’articolo)
604-611
Diffusione
Licenza
CC BY
Visibilità
Pubblico
Status open access
Hybrid
